Drug-trial data

摘要

The Swiss drug giant Roche announced last week that it would give researchers access to anonymized clinical-trial data. Requests for data would need to be approved by an independent panel of experts, the Basel-based company said. The move follows that made last month by GlaxoSmithKline to make data from all its future trials publicly accessible (see Nature 490,322; 2012). The European Medicines Agency intends from next year to make public all trial data submitted to it by industry for drug approvals.